KEYTRUDA
Showing 1 - 25 of 945
Healthy Male Subjects Trial (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection, Pembrolizumab
Not yet recruiting
- Healthy Male Subjects
- Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection
- Pembrolizumab injection
- (no location specified)
Oct 30, 2023
Non Small Cell Lung Cancer Metastatic Trial (Pembrolizumab, Pembrolizumab biosimilar)
Not yet recruiting
- Non Small Cell Lung Cancer Metastatic
- Pembrolizumab
- Pembrolizumab biosimilar
- (no location specified)
Dec 19, 2022
Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,
Not yet recruiting
- Biliary Cancer
- +2 more
- oxaliplatin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
May 13, 2023
Melanoma, Non Small Cell Lung Cancer Trial in Moscow, Omsk, Saint Petersburg (BCD-201, Keytruda)
Active, not recruiting
- Melanoma
- Non Small Cell Lung Cancer
- BCD-201
- Keytruda
-
Moscow, Russian Federation
- +2 more
Feb 13, 2023
Gastric and Gastroesophageal Junction Adenocarcinoma Trial (Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®))
Not yet recruiting
- Gastric and Gastroesophageal Junction Adenocarcinoma
- Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)
- (no location specified)
Aug 17, 2022
Gastric Cancer, Hepatocellular Carcinoma Trial in Beverly Hills, Los Angeles, Torrance (Telatinib, Keytruda)
Recruiting
- Gastric Cancer
- Hepatocellular Carcinoma
- Telatinib
- Keytruda
-
Beverly Hills, California
- +3 more
Sep 1, 2022
Kidney Cancer Trial in Tampa (Pembrolizumab, Interleukin-2)
Active, not recruiting
- Kidney Cancer
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jun 21, 2022
Metastatic Renal Cell Carcinoma Trial in United Kingdom (Cyclophosphamide 50mg, Pembrolizumab 25 mg/1 ML Intravenous Solution
Recruiting
- Metastatic Renal Cell Carcinoma
- Cyclophosphamide 50mg
- Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]
-
Cambridge, United Kingdom
- +3 more
Aug 22, 2022
Hepatocellular Carcinoma Trial (Pembrolizumab)
Active, not recruiting
- Hepatocellular Carcinoma
- Pembrolizumab
- (no location specified)
Dec 15, 2022
Advanced Melanoma Trial in Pittsburgh (Pembrolizumab Injection [Keytruda], Metformin)
Recruiting
- Advanced Melanoma
- Pembrolizumab Injection [Keytruda]
- Metformin
-
Pittsburgh, PennsylvaniaUniv of Pittsburgh Medical Center Hillman Cancer Center
Jan 24, 2022
Cancer, Solid Tumor, Melanoma Trial (KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose
Not yet recruiting
- Cancer
- +16 more
- KVA12123 - Dose Escalation
- +3 more
- (no location specified)
Feb 2, 2023
Adenoid Cystic Carcinoma Trial in Boston (Radiation, Pembrolizumab)
Completed
- Adenoid Cystic Carcinoma
- Radiation
- Pembrolizumab
-
Boston, Massachusetts
- +1 more
Oct 8, 2022
Advanced Biliary Tract Carcinoma Trial in Shanghai (Pembrolizumab Injection [Keytruda], Lenvatinib Mesylate)
Recruiting
- Advanced Biliary Tract Carcinoma
- Pembrolizumab Injection [Keytruda]
- Lenvatinib Mesylate
-
Shanghai, Shanghai, China
- +1 more
Jul 19, 2022
Advanced Hepatocellular Carcinoma Trial (Tegavivint, Pembrolizumab)
Not yet recruiting
- Advanced Hepatocellular Carcinoma
- (no location specified)
Mar 21, 2023
Papillary Renal Cell Carcinoma Trial (Pembrolizumab, Placebo)
Not yet recruiting
- Papillary Renal Cell Carcinoma
- Pembrolizumab
- Placebo
- (no location specified)
Nov 24, 2023
Triple Negative Breast Cancer, Residual Disease Trial (Tetrathiomolybdate, Capecitabine, Pembrolizumab)
Not yet recruiting
- Triple Negative Breast Cancer
- Residual Disease
- Tetrathiomolybdate
- +2 more
- (no location specified)
Nov 15, 2023
Pancreatic Cancer Trial in Baltimore (Gemcitabine, Cisplatin, Pembrolizumab)
Not yet recruiting
- Pancreatic Cancer
- Gemcitabine
- +2 more
-
Baltimore, MarylandSKCCC Johns Hopkins
Aug 16, 2023
Malignant Ascites Trial in Taichung (Nivolumab, Pembrolizumab)
Enrolling by invitation
- Malignant Ascites
-
Taichung, Please Select, TaiwanChina Medical University Hospital
Feb 16, 2023
Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer Trial (ADU-1805, Pembrolizumab)
Not yet recruiting
- Solid Tumor, Adult
- +2 more
- (no location specified)
May 3, 2023